Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Many patients continue using proton pump inhibitors after negative results from tests for reflux disease.

Gawron AJ, Rothe J, Fought AJ, Fareeduddin A, Toto E, Boris L, Kahrilas PJ, Pandolfino JE.

Clin Gastroenterol Hepatol. 2012 Jun;10(6):620-5; quiz e57. doi: 10.1016/j.cgh.2012.02.012. Epub 2012 Feb 22.

2.

Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?

de Bortoli N, Martinucci I, Savarino E, Bellini M, Bredenoord AJ, Franchi R, Bertani L, Furnari M, Savarino V, Blandizzi C, Marchi S.

Neurogastroenterol Motil. 2014 Jan;26(1):28-35. doi: 10.1111/nmo.12221. Epub 2013 Aug 29.

PMID:
23992024
3.

Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.

Clayton SB, Rife CC, Singh ER, Kalbfleisch JH, Castell DO.

Dis Esophagus. 2012 Nov-Dec;25(8):682-6. doi: 10.1111/j.1442-2050.2011.01310.x. Epub 2012 Jan 31.

PMID:
22292567
4.

Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring.

Xiao Y, Liang M, Peng S, Zhang N, Chen M.

J Gastroenterol Hepatol. 2016 Feb;31(2):350-4. doi: 10.1111/jgh.13049.

PMID:
26202002
5.

Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors.

Becker V, Grotz S, Schlag C, Nennstiel S, Beitz A, Haller B, Schmid RM, Meining A, Bajbouj M.

World J Gastroenterol. 2014 Apr 14;20(14):4017-24. doi: 10.3748/wjg.v20.i14.4017.

6.

Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?

Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ.

Am J Gastroenterol. 2008 Oct;103(10):2446-53. doi: 10.1111/j.1572-0241.2008.02033.x. Epub 2008 Aug 5.

PMID:
18684197
7.

Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough.

Ribolsi M, Savarino E, De Bortoli N, Balestrieri P, Furnari M, Martinucci I, Casale M, Greco F, Salvinelli F, Savarino V, Marchi S, Cicala M.

Aliment Pharmacol Ther. 2014 Oct;40(8):966-73. doi: 10.1111/apt.12919. Epub 2014 Aug 11.

8.

Dual Ambulatory pH Monitoring in Patients with Gastroesophageal Reflux Rendered Asymptomatic with Proton Pump Inhibitor Therapy.

Lin D, Triadafilopoulos G.

Dig Dis Sci. 2015 May;60(5):1343-9. doi: 10.1007/s10620-014-3324-y. Epub 2014 Aug 19.

PMID:
25135815
9.

Multichannel intraluminal impedance-pH testing is clinically useful in the management of patients with gastroesophageal reflux symptoms.

Jodorkovsky D, Price JC, Kim B, Dhalla S, Stein EM, Clarke JO.

Dig Dis Sci. 2014 Aug;59(8):1817-22. doi: 10.1007/s10620-014-3080-z. Epub 2014 Feb 23.

PMID:
24563276
10.

Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.

Kohata Y, Fujiwara Y, Machida H, Okazaki H, Yamagami H, Tanigawa T, Watanabe K, Watanabe T, Tominaga K, Arakawa T.

J Gastroenterol Hepatol. 2012 Apr;27 Suppl 3:58-62. doi: 10.1111/j.1440-1746.2012.07074.x.

PMID:
22486873
11.

Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.

Galindo G, Vassalle J, Marcus SN, Triadafilopoulos G.

Dis Esophagus. 2013 Jul;26(5):443-50. doi: 10.1111/j.1442-2050.2012.01381.x. Epub 2012 Aug 2.

PMID:
22862422
12.

Increased prandial air swallowing and postprandial gas-liquid reflux among patients refractory to proton pump inhibitor therapy.

Bravi I, Woodland P, Gill RS, Al-Zinaty M, Bredenoord AJ, Sifrim D.

Clin Gastroenterol Hepatol. 2013 Jul;11(7):784-9. doi: 10.1016/j.cgh.2012.12.041. Epub 2013 Jan 30.

PMID:
23376324
13.

Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease.

Kohata Y, Fujiwara Y, Yamagami H, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Tominaga K, Arakawa T.

J Gastroenterol Hepatol. 2015 Mar;30 Suppl 1:36-40. doi: 10.1111/jgh.12743.

PMID:
25827802
14.
15.

Combined esophageal multichannel intraluminal impedance and pH monitoring (MII -pH) in the diagnostics and treatment of gastroesophageal reflux disease and its complications.

Masiak W, Wallner G, Wallner J, Pedowski T, Solecki M.

Pol Przegl Chir. 2011 Sep;83(9):488-96. doi: 10.2478/v10035-011-0076-7.

PMID:
22166737
16.

A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux (revised 2-26-11).

Lacy BE, Chehade R, Crowell MD.

Am J Gastroenterol. 2011 Sep;106(9):1604-11. doi: 10.1038/ajg.2011.180. Epub 2011 Jun 21.

PMID:
21691342
17.

Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy.

Becker V, Bajbouj M, Waller K, Schmid RM, Meining A.

Aliment Pharmacol Ther. 2007 Nov 15;26(10):1355-60. Epub 2007 Sep 26.

18.

Diagnostic options for patients with refractory GERD.

Fornari F, Sifrim D.

Curr Gastroenterol Rep. 2008 Jun;10(3):283-8. Review.

PMID:
18625140
19.

Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy.

Anandasabapathy S, Jaffin BW.

Ann Otol Rhinol Laryngol. 2006 Aug;115(8):563-70.

PMID:
16944654
20.

Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.

Bytzer P, Jones R, Vakil N, Junghard O, Lind T, Wernersson B, Dent J.

Clin Gastroenterol Hepatol. 2012 Dec;10(12):1360-6. doi: 10.1016/j.cgh.2012.06.030. Epub 2012 Jul 17.

PMID:
22813439

Supplemental Content

Support Center